Cancer PathCHART: Product Downloads and Timelines

Primary Product

Beginning with cases diagnosed in January 1, 2024 and forward, the Cancer PathCHART initiative standards included in the 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List (CPC SMVL) should be used.

• This list designates all tumor site-morphology combinations that are either valid or impossible as determined for sites reviewed by the Cancer PathCHART initiative.
• For sites not reviewed for 2024, the existing standards from 2023 will remain unchanged in this list.
• For cases diagnosed January 1, 2024, and later, the CPC SMVL will serve as the basis for the newly-added Primary Site, Morphology-Type, Beh ICDO3 2024 (N7040) edit, which checks for valid, unlikely and impossible site, histology, and behavior code combinations.

2024 Tumor Site-Morphology Standards

• 2024_CPC_SMVL_08292023.xlsx (XLSX, 4.3 MB)
• 2024_CPC_SMVL_08292023.xml (XML, 25.4 MB)
• 2024_CPC_SMVL_08292023.csv (CSV, 4.0 MB)
• 2024_CPC_SMVL_08292023.json (JSON, 19.2 MB)
• 2024_CPC_SMVL_v1.0_Release_Notes.docx (DOCX, 42 KB)

View larger image

Implementation Timeline

These tumor site-morphology combination standards will be updated annually, with the first updates implemented for cases diagnosed January 1, 2024, and later. In 2024, standards for approximately one-third of tumor sites will be updated by Cancer PathCHART. The remaining two-thirds of tumor sites will use 2023 standards. For cases diagnosed in 2025, approximately two-thirds of tumor sites will have site-morphology combination standards updated. For cases diagnosed 2026 and later, it is anticipated that all tumor sites will have site-morphology combination standards updated by Cancer PathCHART.